Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 4/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.41 |
| ▸ | NMT1 | P30419 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 3/20 | 0.36 |
| ▸ | BACE1 | P56817 | 3/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4545280 | 0.91 | NTRK1 (0.41) | ABL1NTRK1FFAR4 | |
| SCHEMBL1050366 | 0.84 | SLC6A9 (0.46) | ABL1NTRK1FFAR4FFAR1 | |
| SCHEMBL4545285 | 0.82 | DDHD2 (0.42) | ABL1NTRK1FFAR4FFAR1 | |
| SCHEMBL1053472 | 0.82 | MGLL (0.37) | ABL1NTRK1NMT1 | |
| SCHEMBL1052404 | 0.82 | NTRK1 (0.40) | ABL1NTRK1FFAR4FFAR1 | |
| SCHEMBL1052720 | 0.81 | FFAR4 (0.41) | ABL1NTRK1FFAR4FFAR1 | |
| SCHEMBL1050669 | 0.81 | MGLL (0.40) | CNR2 | |
| SCHEMBL1051680 | 0.78 | HDAC8 (0.40) | BACE1 | |
| SCHEMBL4545319 | 0.78 | SLC6A9 (0.45) | ABL1FFAR4FFAR1 | |
| SCHEMBL4545310 | 0.76 | SLC6A9 (0.47) | NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120116095-A1 | GLYCINE TRANSPORTER INHIBITORS | TAISHO PHARMACEUTICAL C0., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20120116095-A1 | GLYCINE TRANSPORTER INHIBITORS | TAISHO PHARMACEUTICAL C0., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116095-A1 | GLYCINE TRANSPORTER INHIBITORS | SLC6A5, SLC1A2, SLC18A2 | ABL1 2937/4885NTRK1 3262/4885FFAR4 3234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.